Dr. David E. Prestegui Muñoz, MD

Adult neurocardiology: stroke–heart syndromes, arrhythmias, syncope/dysautonomia, HF & cognition. EN/ES. Human first, proud husband. 🧠🫀

[NefrologíaHGM @hgm_nefrologia]

Convocatoria abierta para el 1er Posgrado de Alta Especialidad en Enfermedades Glomerulares y Onconefrología en México y Latinoamérica. 
Aval: UNAM y Hospital General de México "Dr. Eduardo Liceaga"
Dirigido a nefrólogos nacionales e internacionales
Registro: 30 nov –11 dic 2026

[Dr. David E. Prestegui Muñoz, MD @Dr_Prestegui]

Aneurisma o pseudoaneurisma 🫀

[Dr. Yonni @kiddiewise_]

You were checking her blood pressure, and this happened. What are you diagnosing?

[Dr. David E. Prestegui Muñoz, MD @Dr_Prestegui]

@abdulhamid_199 Parece una cebolla, pero es un corpúsculo de Pacini (mecanorreceptor de la dermis). 🧅🔬
Aunque su estructura concéntrica es clásica, cuidado: según el tejido, hay patologías que simulan este mismo patrón. En histología, una imagen sin contexto te puede engañar. 🩺

[Jorge Faerron @cardiopedhnn]

The ventricular-structure relationship:: the #Torrent_Guasp_ventricular_myocardial_band (Part I: normal heart)

https://t.co/kzNf7TzP6V

[Sociedad Mexicana de Cardiología @smexcardiologia]

🗓️ Cada miércoles compartimos una #CardioClave basada en casos clínicos reales.

🫀 Hoy te compartimos: Tetralogía de Fallot reparada: el seguimiento es clave.

👉Desliza para ver los videos.
📱Contenido elaborado por el Capítulo de Imagen Multimodal. @cardiacandvascularimages

#SoySMC #EducaciónMédica #Cardiología

[Dr. David E. Prestegui Muñoz, MD @Dr_Prestegui]

@ArgaizR @NephroP @nephrothaniel Que crack felicidades!!

[Dr. David E. Prestegui Muñoz, MD @Dr_Prestegui]

@DeNefrologos @ERNESTOAE4 @DraPettite

[Dr. David E. Prestegui Muñoz, MD @Dr_Prestegui]

@MicieliA_MD 😵

[Jonathan Chávez @JonathanNefro]

No hay necesidad de tomar gasometrias arteriales.

En la cohorte más grande analizada, desarrollaron formulas para estimar los valores arteriales de pCO2, pH y bicarbonato (con correlación casi perfecta) derivado punción venosa

@Dan_Batlle

Kidney360 2026
10.34067/KID.0000001113

[Jamir Pitton Rissardo @theneurolander]

Drug-induced myoclonus (DIM)

DIM is more common than clinicians realize

Our systematic review screened 12,097 PubMed articles and identified 1,115 cases of DIM

https://t.co/9tnvrUtL7D
https://t.co/hbOCaB7wmk
#mdpimedicina
via @MdpiMedicina

1/

[Laura Fuentes Méndez @laufuentesm]

Incredibly proud to see @DraPettite presenting her work as a Rapid-fire at #ASDIN2026!
The study shows that kidney biopsy in low-volume kidneys (<100 ml) is safe and clinically useful, with a direct impact on treatment decisions. Outstanding 🎉 @hgm_nefrologia @adom92 @galindozip

[Dr. David E. Prestegui Muñoz, MD @Dr_Prestegui]

Roto...

[Dr. David E. Prestegui Muñoz, MD @Dr_Prestegui]

#CardioTwitter #RVPACoupling #StructuralHeart #TAVI #MitraClip #EchoFirst #RightVentricle #Hemodynamics #Cardiologia #MedEd

[NefrologíaHGM @hgm_nefrologia]

Jornada intensa con TPE simultáneo en vasculitis. Nefrología crítica y terapias extracorpóreas en acción en HGM @galindozip @DraPettite @UnaLinnys
Foto autorizada.

[💫 @evabega]

Cuando fui a firmar contrato

[Bashaer Gheyath MD FACC 🫀👩🏻‍⚕️ @Bgheyath]

Dr Nishimura 🫀✨This slide never gets old.
RHC hemodynamics — RA, PAWP, RA/PAWP & PAPi — remain the backbone for LV/RV/BiV failure assessment before LVAD.
Elegant physiology, real consequences.
#ICSC2026 #CardioTwitter

[Dr. David E. Prestegui Muñoz, MD @Dr_Prestegui]

🧵 Nuevas Guías AHA/ASA 2026 para el ACV Isquémico Agudo #ACV #Stroke #Salud #Medicina #Neurología

[Jonathan Chávez @JonathanNefro]

A pesar de la glucosuria inducida por los iSGLT2 no se generan más infecciones urinarias; esto se explica porque el fármaco induce una defensa tubular, al ↓C1q que mejora la capacidad intrínseca antibacteriana

Kidney Int 2026
https://t.co/uy8WFTDyKy.

[Dr. Filippo Cademartiri @FCademartiri]

🚨 Can echocardiography really exclude HFpEF? New data say: not reliably.

A large, invasive hemodynamics–validated study tested the updated 2025 ASE diastolic function grading algorithm in patients with confirmed HFpEF — and the results are eye-opening. 👀

🔍 Key finding:
Among ambulatory patients with invasively proven HFpEF, ~68% were classified as “normal” or Grade 1 diastolic dysfunction by the new ASE criteria. Yet >60% of these patients already had elevated filling pressures at rest, and many worsened dramatically with exercise.

🏃‍♂️ Stress echo underperformed:
In patients labeled Grade 1 (where exercise testing is recommended), the ASE 2025 stress criteria detected HFpEF in only ~10% — a false-negative rate >90%. Even under “best-case” assumptions, sensitivity remained poor.

🏥 Volume status matters:
Diastolic grades shifted substantially between decompensated and recompensated states. After diuresis, over 50% of hospitalized HFpEF patients reverted to normal or Grade 1, highlighting how load-dependent and unstable diastolic grading can be.

📉 Diagnostic performance:
Overall discrimination for HFpEF vs non-cardiac dyspnea was modest (AUC ~0.61) — inferior to probability-based tools like H₂FPEF, especially when combined with functional testing.

⚠️ Prognostic paradox:
Patients with HFpEF labeled “normal” or Grade 1 still had a ~5-fold higher risk of death or HF hospitalization compared with controls.

💡 Bottom line:
🛑 Normal diastolic function ≠ no HFpEF.
Echocardiography remains essential — but diastolic grades must be interpreted within pretest probability frameworks, not used in isolation to rule out disease.